The FDA has approved a new antibiotic combination called Emblaveo to treat serious infections of the abdomen in adults who have few or no other treatment options. It will be given through an IV and used with another antibiotic called metronidazole.

Emblavio is designed to treat infections caused by bacteria that are resistant to common antibiotics. These bacteria produce enzymes that break down antibiotics, making them less effective. Antimicrobial resistance (AMR) has been growing over the years, turning simple infections into serious health risks. In 2021, AMR led to over a million deaths worldwide, highlighting the need for new treatments.

Emblavio combines aztreonam, an antibiotic that stops bacteria from growing, and avibactam, which blocks enzymes that break down the antibiotic. Together, they help fight resistant bacteria and treat tough infections more effectively. Both drugs had already been approved separately by the FDA. Head over to WebMD to read the full story.